A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Th… (NCT07304258) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
China30 participantsStarted 2025-12-12
Plain-language summary
This study aims to evaluate the efficacy and safety of HIPEC combined with NIPS and tislelizumab conversion therapy for gastric/gastroesophageal junction cancer with positive cytology alone (CY1P0) or a Peritoneal Carcinomatosis Index (PCI) ≤10
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Treatment-naïve patients who have not received chemotherapy, radiotherapy, or any other antitumor therapy prior to the start of the clinical trial;
✓. Age between 18 and 75 years;
✓. Male or non-pregnant, non-lactating female;
✓. Gastric or gastroesophageal junction adenocarcinoma confirmed by gastroscopy and pathological diagnosis;
✓. HER-2 negative by immunohistochemistry (IHC), and PD-L1 CPS ≥1;
✓. Laparoscopic exploration confirming either positive cytology alone (P0CY1) or peritoneal metastasis (PCI score ≤10);
✕. Inability to comply with the study protocol or procedures;
✕. Known HER2-positive status;
✕. Known diagnosis of squamous cell carcinoma, undifferentiated carcinoma, or other histological types of gastric cancer, or adenocarcinoma mixed with other histological types;
✕. Current conditions or diseases affecting drug absorption;